Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Patients with cancer are at high risk for severe COVID-19 and show impaired immune responses after vaccination. Specifically, levels of neutralizing antibodies against variants of concern, including Delta (B.1.617.2) and Omicron (B.1.1.529), are lower in patients with cancer than in those without. Fourth vaccination dose or administration of monoclonal neutralizing antibodies, such as tixagevimab and cilgavimab, is being considered, although data supporting this strategy are limited, especially in the context of currently circulating variants, such as BA.4.
JAMA Oncology , article en libre accès, 2021